Sonus Pharmaceuticals and OncoGenex Technologies complete business combination

On August 21, 2008, OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company had completed its acquisition of OncoGenex Technologies and that NASDAQ had approved the commencement of trading in the Company's common stock the same day. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split. OncoGenex Pharmaceuticals was advised in this transaction by a team from Fasken Martineau led by Iain Mant and that included, among others, Lata Casciano, Prentice Durbin and Frank Schober (tax).